3,761 views
It is mainly symptomatic: in the last 10 years, attempts have been made above all to re-establish adequate quantities of acetylcholine in the brains of Alzheimer's patients with some cholinesterase inhibitor drugs. In fact, the neurotransmitter most involved in the initial stages of the disease is acetylcholine, of which patients have a serious deficit at the level of some nuclei found in the basal frontal brain. These are nuclei that lose neurons and reduce cholinergic afferents to the hippocampal areas. Another therapeutic attempt involves drugs that act on other neurotransmitters, such as drugs that act by inhibiting NMDA receptors with excitotoxic function. But what is the ideal drug? The one that can block the neuropathological process that is at the basis of the disease, that is, the deposition of beta-amyloid and the development of neurotoxicity. At the experimental stage, there are drugs that can block the enzymes that produce amyloid, but also anti-inflammatory drugs and others capable of stopping oxidative mechanisms that may be the cause of the disease.